Boston Scientific — Third Quarter 2026 Earnings Summary

Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, representing a 1.5% increase on a reported, operational, and organic basis compared to the prior year. The company recorded GAAP net income of $582 million, or $0.40 per share, while adjusted earnings per share reached $0.73. Full-year 2026 net sales growth is now estimated at approximately 4.25% on a reported basis, with adjusted EPS guidance set between $3.16 and $3.18. Additionally, the company announced FDA clearances for new urology and cardiovascular devices and initiated enrollment in the Elite AF clinical trial.